Impulse Dynamics, a Stuttgart, Germany-based developer of Cardiac Contractility Modulation (CCM) technology for the treatment of Chronic Heart Failure (CHF), closed a $45m funding round.
The round was led by Goldstone Investment, with participation from other unnamed investors.
The company will use the funds for its continued product development and market expansion efforts.
Led by Dr. Simos Kedikoglou, Chief Executive Officer, Impulse Dynamics focuses on the development of electrical therapies for the treatment of chronic heart failure. The company’s CCM therapy is delivered by an implantable optimizer device that administers non-excitatory electric pulses to the heart muscle, initiating multiple biochemical and neurohormonal changes to the myocardium. As a result, the contractility of the myocardium increases with no concomitant increase in oxygen consumption, enabling the heart to work more efficiently.
The technology has already been launched in Europe and is available in cardiology centers in a number of countries. It has been implanted in over 3,500 patients.